Aquaporin-4 (AQP4) is a water channel protein normally enriched at astrocytic endfeet that interface with cerebral blood vessels. Loss of this perivascular polarization of AQP4 has been reported in multiple vascular and neurodegenerative conditions. The present preprint examined how the localization of AQP4 affects pathology and outcome in a model of cerebral amyloid angiopathy associated with prion protein.
The experimental system used a mouse model of cerebral amyloid angiopathy driven by expression of GPI-anchorless PrP(C). In this prion-CAA model, amyloid accumulates on blood vessels and the study authors assessed the relationship between vascular amyloid deposition, astrocyte endfeet, and AQP4 distribution.
To experimentally displace AQP4 from astrocyte endfeet, the investigators deleted alpha-syntrophin (Snta1-/-). Alpha-syntrophin is a scaffolding protein required for normal perivascular localization of AQP4. The Snta1-/- manipulation therefore reduced polarized perivascular expression of AQP4 without directly targeting the AQP4 gene itself.
Mice with prion-CAA that also carried Snta1 deletion (resulting in AQP4 mislocalization) showed a marked prolongation in survival compared with prion-CAA mice with intact AQP4 polarization. The source reports this as a key outcome, indicating that altering astrocytic water channel localization had measurable effects on lifespan in this disease model. Specific numerical survival data, hazard ratios, or p values were not provided in the source summary.
The study found reduced microglial inflammation in prion-CAA mice lacking perivascular AQP4. Levels of the complement protein C1q were also reduced in Snta1-/- prion-CAA mice. These observations link the protective effect on survival to an attenuation of innate immune activation in the brain rather than to a reduction in vascular amyloid itself.
Alongside reductions in inflammatory markers, synaptic structural proteins were better maintained in the AQP4-mislocalized mice. This suggests that preserving synaptic integrity may be an intermediate correlate of the improved survival and reduced inflammation, although the source does not detail which synaptic proteins were assessed or the magnitude of preservation.
Importantly, the reported level and distribution of prion aggregates were similar across genotypes, indicating that mislocalizing AQP4 did not alter prion conversion or spread in this model. Thus, the survival benefit and reduced neuroinflammation occurred without detectable changes in the underlying prion burden.
Based on these findings, the authors propose that reducing AQP4 water channel function or its perivascular localization slows decline in a vascular amyloid disease model by diminishing neuroinflammation. The data support a model in which altered astrocyte water handling at the gliovascular interface influences inflammatory responses and synaptic maintenance, thereby affecting clinical course independent of aggregate load.
This report is a preprint and has not been peer reviewed. The source summary does not provide experimental details such as sample sizes, exact survival statistics, time courses, methods for assessing microglial activation, quantitative measures of synaptic proteins, or imaging and biochemical methods used to evaluate prion aggregates. Those details were not reported in the provided source text and would need to be consulted in the full manuscript for assessment of rigor and reproducibility.
The work was posted as a bioRxiv preprint and had not been certified by peer review at the time of posting. Funding sources declared include multiple grants from the National Institute of Neurological Disorders and Stroke, support from the National Institute on Aging training award, and a University of California postdoctoral fellowship. The authors declared no competing interests in the source summary.